News & events

What's new

RSS
Oct 2023 (1) Mar 2023 (564) Feb 2023 (463) Jan 2023 (435) Dec 2022 (329) Nov 2022 (348) Oct 2022 (247) Sep 2022 (283) Aug 2022 (173) Jul 2022 (263) Jun 2022 (357) May 2022 (224) Apr 2022 (244)
Date Content
30/03/2023 Herbal medicinal product: Juniperi galbulus (pseudo-fructus), Juniperi galbulus (pseudo-fructus), F: Assessment finalised (updated)
30/03/2023 Herbal medicinal product: Malvae sylvestris flos, Malvae sylvestris flos, C: ongoing call for scientific data (updated)
30/03/2023 Herbal medicinal product: Malvae folium, Malvae folium, C: ongoing call for scientific data (updated)
30/03/2023 Herbal medicinal product: Matricariae aetheroleum, Matricariae aetheroleum, C: ongoing call for scientific data (updated)
30/03/2023 Herbal medicinal product: Lecithinum ex soya, Lecithinum ex soya, C: ongoing call for scientific data (updated)
30/03/2023 Herbal medicinal product: Soiae oleum raffinatum, Soiae oleum raffinatum, C: ongoing call for scientific data (updated)
30/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Verquvo, Vericiguat, PM: decision on the application for modification of an agreed PIP, P/0454/2022 (updated)
30/03/2023 Herbal medicinal product: Fragariae folium, Fragariae folium, C: ongoing call for scientific data (updated)
30/03/2023 Summary of opinion: Bimervax, (COVID-19 Vaccine (recombinant, adjuvanted)), 30/03/2023, Positive
30/03/2023 News and press releases: EMA recommends approval of Bimervax as a COVID-19 booster vaccine
30/03/2023 Human medicines European public assessment report (EPAR): Dasatinib Accord, dasatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, 24/03/2022, Generic, 1, Withdrawn (updated)
30/03/2023 Human medicines European public assessment report (EPAR): Dasatinib Accordpharma, dasatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive, 24/03/2022, Generic, 1, Withdrawn (updated)
30/03/2023 Clinical Trials Information System (CTIS) bitesize talk: IMPD-Q only submission , Online, 15:30 - 17:00 Amsterdam time (CEST), from 10/05/2023 to 10/05/2023
30/03/2023 Public information on medicine shortages (updated)
30/03/2023 Quarterly system demo - Q1 2023 , Online, 09:00 - 13:00 Amsterdam time (CET), from 22/03/2023 to 22/03/2023 (updated)
30/03/2023 Minutes: Meeting Summary of the Medicine Shortages (SPOC) Working Party 15 February 2023
30/03/2023 Minutes: Meeting Summary of the Medicine Shortages (SPOC) Working Party 18 January 2023
30/03/2023 Minutes: Meeting Summary of the Medicine Shortages (SPOC) Working Party 13 December 2022
30/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Givinostat, PM: decision on the application for modification of an agreed PIP, P/0513/2022
30/03/2023 Medicine Shortages SPOC Working Party meetings
30/03/2023 CVMP Interested Parties’ meeting , European Medicines Agency, Amsterdam, the Netherlands, 10:00-12:00 CEST (Amsterdam time), from 24/05/2023 to 24/05/2023
30/03/2023 Leaflet: Stakeholder engagement highlights 2022 (updated)
30/03/2023 Other: HMPC: overview of assessment work - priority list (updated)
30/03/2023 Other: Records of data processing for Data Analysis and Real World Interrogation Network (DARWIN EU®)
30/03/2023 Human medicines European public assessment report (EPAR): HyQvia, Human normal immunoglobulin, Immunologic Deficiency Syndromes, 16/05/2013, 19, Authorised (updated)
30/03/2023 Human medicines European public assessment report (EPAR): Jyseleca, filgotinib maleate, Arthritis, Rheumatoid, 24/09/2020, Patient safety, Additional monitoring, 8, Authorised (updated)
30/03/2023 Human medicines European public assessment report (EPAR): Rinvoq, upadacitinib, Arthritis, Rheumatoid, 16/12/2019, Patient safety, Additional monitoring, 13, Authorised (updated)
30/03/2023 Human medicines European public assessment report (EPAR): Olumiant, baricitinib, Arthritis, Rheumatoid, 13/02/2017, Patient safety, 10, Authorised (updated)
30/03/2023 Human medicines European public assessment report (EPAR): Cibinqo, Abrocitinib, Dermatitis, Atopic, 09/12/2021, Patient safety, Additional monitoring, 3, Authorised (updated)
30/03/2023 Focus group meeting on bacteriophages , European Medicines Agency, Amsterdam, the Netherlands, 09:30-16:30 CEST (Amsterdam time), from 11/05/2023 to 11/05/2023
30/03/2023 Human medicines European public assessment report (EPAR): Xeljanz, Tofacitinib, Arthritis, Rheumatoid, 22/03/2017, 25/04/2013, Patient safety, 26, Authorised (updated)
30/03/2023 Referral: Janus kinase inhibitors (JAKi) , tofacitinib, abrocitinib, baricitinib, upadacitinib, filgotinib, Article 20 procedures, European Commission final decision, 23/01/2023, 10/03/2023, 30/03/2023 (updated)
30/03/2023 Direct healthcare professional communication (DHPC): Updated recommendations to minimise the risks of malignancy, major adverse cardiovascular events, serious infections, venous thromboembolism and mortality with use of Janus kinase inhibitors (JAKi), Active substance: Abrocitinib, filgotinib, baricitinib, upadacitinib, Tofacitinib, DHPC type: Referral - Article 20 procedure, Last updated: 30/03/2023
29/03/2023 Human medicines European public assessment report (EPAR): Tepadina, thiotepa, Hematopoietic Stem Cell Transplantation, 15/03/2010, 19, Authorised (updated)
29/03/2023 Report: HMPC meeting report on European Union herbal monographs, guidelines and other activities - 13-15 March 2023
29/03/2023 Agenda: Agenda of the PDCO meeting 28-31 March 2023
29/03/2023 Human medicines European public assessment report (EPAR): Kineret, anakinra, Arthritis, Rheumatoid; COVID-19 virus infection, 08/03/2002, 33, Authorised (updated)
29/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Xofluza, Baloxavir marboxil, PM: decision on the application for modification of an agreed PIP, P/0486/2021 (updated)
29/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Vitrakvi, Larotrectinib, PM: decision on the application for modification of an agreed PIP, P/0487/2021 (updated)
29/03/2023 Human medicines European public assessment report (EPAR): Azacitidine Accord, azacitidine, Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute, 13/02/2020, Generic, 6, Authorised (updated)
29/03/2023 Human medicines European public assessment report (EPAR): Imvanex, modified vaccinia Ankara - Bavarian Nordic (MVA-BN) virus, Smallpox Vaccine; Monkeypox virus, 31/07/2013, Additional monitoring, Exceptional circumstances, 25, Authorised (updated)
29/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Tabelecleucel, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0490/2020 (updated)
29/03/2023 Human medicines European public assessment report (EPAR): Alecensa, alectinib hydrochloride, Carcinoma, Non-Small-Cell Lung, 16/02/2017, Additional monitoring, 14, Authorised (updated)
29/03/2023 Other: Network ICT Advisory Committee (NICTAC) - List of nominated members (updated)
29/03/2023 Human medicines European public assessment report (EPAR): Sancuso, granisetron, Vomiting; Cancer, 20/04/2012, 14, Authorised (updated)
29/03/2023 Human medicines European public assessment report (EPAR): Otezla, apremilast, Arthritis, Psoriatic; Psoriasis, 15/01/2015, 20, Authorised (updated)
29/03/2023 Human medicines European public assessment report (EPAR): Puregon, follitropin beta, Infertility; Hypogonadism, 02/05/1996, 34, Authorised (updated)
29/03/2023 Human medicines European public assessment report (EPAR): Tecovirimat SIGA, Tecovirimat, Poxviridae Infections; Cowpox; Monkeypox; Vaccinia; Smallpox, 06/01/2022, Additional monitoring, 1, Authorised (updated)
29/03/2023 Human medicines European public assessment report (EPAR): Aldurazyme, laronidase, Mucopolysaccharidosis I, 09/06/2003, 23, Authorised (updated)
29/03/2023 Orphan designation: Govorestat for the: Treatment of galactosaemia, 21/06/2022, Positive (updated)
29/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Soticlestat, PM: decision on the application for modification of an agreed PIP, P/0491/2021 (updated)
29/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Cyclophosphamide, PM: decision on the application for modification of an agreed PIP, P/0490/2021 (updated)
29/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Flucelvax Tetra, Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H1N1),Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H3N2),Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Yamagata lineage),Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Victoria lineage) [QIVc], PM: decision on the application for modification of an agreed PIP, P/0492/2021 (updated)
29/03/2023 Orphan designation: Iodine (131I) iobenguane for the: Treatment of neuroblastoma, 31/01/2008, Positive (updated)
29/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Nuvaxovid, Severe acute respiratory syndrome coronavirus 2 recombinant spike protein nanoparticle vaccine/ matrix-M1 adjuvant (NVX-CoV2373), PM: decision on the application for modification of an agreed PIP, P/0483/2021 (updated)
29/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Deferoxamine (mesylate),histidine,tryptophan,aspartic acid,n-acetyl-histidine (monohydrate),glycine,alpha-ketoglutaric acid,arginine,potassium chloride,magnesium chloride (hexahydrate),calcium chloride (dihydrate),sodium chloride,alanine,3,4-dimethoxy-N-methylbenzohydroxamic acid (Custodiol-N), PM: decision on the application for modification of an agreed PIP, P/0484/2021 (updated)
29/03/2023 Human medicines European public assessment report (EPAR): Febuxostat Mylan, febuxostat, Hyperuricemia; Arthritis, Gouty; Gout, 15/06/2017, Generic, 9, Authorised (updated)
29/03/2023 Human medicines European public assessment report (EPAR): Azopt, brinzolamide, Glaucoma, Open-Angle; Ocular Hypertension, 09/03/2000, 28, Authorised (updated)
29/03/2023 Human medicines European public assessment report (EPAR): Myozyme, alglucosidase alfa, Glycogen Storage Disease Type II, 28/03/2006, 23, Authorised (updated)
29/03/2023 Human medicines European public assessment report (EPAR): Kesimpta, ofatumumab, Multiple Sclerosis, Relapsing-Remitting, 26/03/2021, Additional monitoring, 6, Authorised (updated)
29/03/2023 Human medicines European public assessment report (EPAR): Glivec, imatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma; Gastrointestinal Stromal Tumors; Dermatofibrosarcoma; Myelodysplastic-Myeloproliferative Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Hypereosinophilic Syndrome, 07/11/2001, Additional monitoring, 45, Authorised (updated)
29/03/2023 Human medicines European public assessment report (EPAR): Sivextro, tedizolid phosphate, Soft Tissue Infections; Skin Diseases, Bacterial, 23/03/2015, 21, Authorised (updated)
29/03/2023 Human medicines European public assessment report (EPAR): Nyvepria, pegfilgrastim, Neutropenia, 18/11/2020, Additional monitoring, Biosimilar, 5, Authorised (updated)
29/03/2023 Human medicines European public assessment report (EPAR): Eucreas, vildagliptin, metformin hydrochloride, Diabetes Mellitus, Type 2, 14/11/2007, 23, Authorised (updated)
29/03/2023 Human medicines European public assessment report (EPAR): Memantine Mylan, memantine hydrochloride, Alzheimer Disease, 21/04/2013, Generic, 10, Authorised (updated)
29/03/2023 Human medicines European public assessment report (EPAR): Mimpara, cinacalcet hydrochloride, Hypercalcemia; Parathyroid Neoplasms; Hyperparathyroidism, 22/10/2004, 25, Authorised (updated)
29/03/2023 Human medicines European public assessment report (EPAR): Arsenic trioxide Mylan, Arsenic trioxide, Leukemia, Promyelocytic, Acute, 01/04/2020, Generic, 4, Authorised (updated)
29/03/2023 Other: Questions and answers on the protection of commercially confidential information and personal data while using CTIS (updated)
29/03/2023 Report: Key performance indicators (KPIs) to monitor the European clinical trials environment (1-28 February 2023, edition 11)
29/03/2023 Referral: Pholcodine-containing medicinal products , pholcodine, Article 107i procedures, European Commission final decision, 14/12/2022, 06/03/2023, 29/03/2023 (updated)
28/03/2023 Other: Nominations to the Network Portfolio Advisory Group (updated)
28/03/2023 Network Portfolio (updated)
28/03/2023 Other: Questions and answers on describing adverse events in the product information (summary of product characteristics (SPC) and package leaflet (PL)) (updated)
28/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Dupixent, dupilumab, W: decision granting a waiver in all age groups for all conditions or indications, P/0121/2021 (updated)
28/03/2023 Human medicines European public assessment report (EPAR): Deferasirox Mylan, deferasirox, Iron Overload; beta-Thalassemia, 26/09/2019, Generic, 9, Authorised (updated)
28/03/2023 Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Urologic Neoplasms; Mesothelioma; Colorectal Neoplasms, 19/06/2015, 52, Authorised (updated)
28/03/2023 News and press releases: DARWIN EU® has completed its first studies and is calling for new data partners
28/03/2023 Data Analysis and Real World Interrogation Network (DARWIN EU) (updated)
28/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Aimovig, erenumab, PM: decision on the application for modification of an agreed PIP, P/0475/2021 (updated)
28/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Besponsa, inotuzumab ozogamicin, PM: decision on the application for modification of an agreed PIP, P/0478/2021 (updated)
28/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Cresemba, Isavuconazonium sulfate, PM: decision on the application for modification of an agreed PIP, P/0479/2021 (updated)
28/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Vaxzevria (previously COVID-19 Vaccine AstraZeneca), COVID-19 vaccine (ChAdOx1-S [recombinant]) (AZD1222), PM: decision on the application for modification of an agreed PIP, P/0559/2021 (updated)
28/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Breyanzi, Lisocabtagene maraleucel, PM: decision on the application for modification of an agreed PIP, P/0558/2021 (updated)
28/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Lydisilka, Estetrol,drospirenone, PM: decision on the application for modification of an agreed PIP, P/0561/2021 (updated)
28/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Palovarotene, PM: decision on the application for modification of an agreed PIP, P/0562/2021 (updated)
28/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Fully human IgG1 RB-1 YTE anti-RSV F monoclonal antibody (MK-1654), PM: decision on the application for modification of an agreed PIP, P/0554/2021 (updated)
27/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): glycopyrronium bromide, PM: decision on the application for modification of an agreed PIP, P/0565/2021 (updated)
27/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Bavencio, avelumab, PM: decision on the application for modification of an agreed PIP, P/0546/2021 (updated)
27/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Comirnaty, Tozinameran, PM: decision on the application for modification of an agreed PIP, P/0547/2021 (updated)
27/03/2023 Other: Records of data processing activity relating to staff engagement surveys (public)
27/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Tirzepatide, PM: decision on the application for modification of an agreed PIP, P/0540/2021 (updated)
27/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Synthetic double-stranded siRNA oligonucleotide directed against lactate dehydrogenase A mRNA and containing four modified nucleosides which form a ligand cluster of four N-acetylgalactosamine residues (DCR-PHXC), PM: decision on the application for modification of an agreed PIP, P/0541/2021 (updated)
27/03/2023 List of medicines under additional monitoring (updated)
27/03/2023 Medicines under additional monitoring: List of medicinal products under additional monitoring (updated)
27/03/2023 Medicines under additional monitoring: List of medicinal products under additional monitoring (updated)
27/03/2023 ICH Guideline Q5A(R2) on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin - Scientific guideline (updated)
27/03/2023 Orphan designation: edaravone for the: Treatment of amyotrophic lateral sclerosis, 16/12/2014, Positive (updated)
27/03/2023 Fifth EMA-EFPIA annual bilateral meeting , Hybrid, 14:00 - 16:00 Amsterdam time (CET), from 07/02/2023 to 07/02/2023 (updated)
27/03/2023 Herbal medicinal product: Hippocastani cortex, Hippocastani cortex, F: Assessment finalised (updated)
27/03/2023 Report: List of withdrawn medicinal products in accordance with Art. 123(4) of the Directive (1 January - 31 December 2022) (updated)
27/03/2023 Other: About us - European Medicines Agency (EMA) (updated)
27/03/2023 Orphan designation: Recombinant adeno-associated viral vector containing the human RPGR gene for the: Treatment of retinitis pigmentosa caused by mutations in the RPGR gene, 30/05/2016, Positive (updated)
27/03/2023 Orphan designation: (S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidine-3-yl)chroman-2-carboxamide hydrochloride for the: Treatment of maternally-inherited diabetes and deafness, 28/06/2019, Positive (updated)
27/03/2023 Orphan designation: (S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride for the: Treatment of mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes, 10/08/2015, Positive (updated)
27/03/2023 Orphan designation: (S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride for the: Treatment of Leigh syndrome, 15/10/2014, Positive (updated)
27/03/2023 Human medicines European public assessment report (EPAR): Nuvaxovid, SARS-CoV-2 recombinant spike protein, COVID-19 virus infection, 20/12/2021, Additional monitoring, Conditional approval, 8, Authorised (updated)
27/03/2023 Direct healthcare professional communication (DHPC): Pholcodine-containing medicinal products no longer available on the EU market, Active substance: pholcodine, DHPC type: Referral - Article 107i procedure, Last updated: 27/03/2023
27/03/2023 Orphan designation: Autologous CD34+ cells transfected with lentiviral vector containing the Wiskott-Aldrich syndrome protein gene (etuvetidigene autotemcel) for the: Treatment of Wiskott-Aldrich syndrome, 06/06/2012, Positive (updated)
27/03/2023 Orphan designation: Adeno-associated viral vector serotype LK03 encoding human ornithine transcarbamylase for the: Treatment of ornithine transcarbamylase deficiency, 20/03/2017, Positive (updated)
24/03/2023 Fourth Industry Standing Group (ISG) meeting , Online, from 21/03/2023 to 21/03/2023 (updated)
24/03/2023 Referral procedures: human medicines (updated)
24/03/2023 Human medicines European public assessment report (EPAR): Imraldi, adalimumab, Spondylitis, Ankylosing; Arthritis, Rheumatoid; Uveitis; Colitis, Ulcerative; Psoriasis; Arthritis, Psoriatic; Crohn Disease; Hidradenitis Suppurativa; Arthritis, 24/08/2017, Biosimilar, 20, Authorised (updated)
24/03/2023 Human medicines European public assessment report (EPAR): Comirnaty, Single-stranded, 5’-capped messenger RNA produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2, COVID-19 virus infection, 21/12/2020, Patient safety, Additional monitoring, 41, Authorised (updated)
24/03/2023 Human medicines European public assessment report (EPAR): Briviact (in Italy: Nubriveo), Brivaracetam, Epilepsy, 13/01/2016, 20, Authorised (updated)
24/03/2023 Summary of opinion: Newflend ND H9, turkey herpes virus, strain rHVT/ND expressing Newcastle disease virus, live, 23/03/2023, Positive
24/03/2023 News and press releases: Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 21-22 March 2023
24/03/2023 Human medicines European public assessment report (EPAR): Lynparza, Olaparib, Ovarian Neoplasms, 16/12/2014, 20, Authorised (updated)
24/03/2023 Human medicines European public assessment report (EPAR): Xromi, hydroxycarbamide, Anemia, Sickle Cell, 01/07/2019, 6, Authorised (updated)
24/03/2023 Human medicines European public assessment report (EPAR): Symkevi, tezacaftor, ivacaftor, Cystic Fibrosis, 31/10/2018, Orphan, Additional monitoring, 11, Authorised (updated)
24/03/2023 Human medicines European public assessment report (EPAR): Giapreza, Angiotensin II acetate, Hypotension; Shock, 23/08/2019, Additional monitoring, 3, Authorised (updated)
24/03/2023 Human medicines European public assessment report (EPAR): Opsumit, Macitentan, Hypertension, Pulmonary, 20/12/2013, Orphan, 22, Authorised (updated)
24/03/2023 Human medicines European public assessment report (EPAR): Kanjinti, trastuzumab, Stomach Neoplasms; Breast Neoplasms, 16/05/2018, Biosimilar, 10, Authorised (updated)
24/03/2023 Handling competing interests (updated)
24/03/2023 Other: Fergus Sweeney - Assessment outcome of occupational activities after leaving the service (March 2023)
24/03/2023 Other: Agnes Saint-Raymond - Assessment outcome of occupational activities after leaving the service (March 2023)
24/03/2023 Human medicines European public assessment report (EPAR): Levetiracetam Accord, levetiracetam, Epilepsy, 03/10/2011, Generic, 15, Authorised (updated)
24/03/2023 Human medicines European public assessment report (EPAR): Bavencio, avelumab, Neuroendocrine Tumors, 18/09/2017, Additional monitoring, 15, Authorised (updated)
24/03/2023 Other: Acceptability of IU as abbreviation for International Units in the strength of human medicinal products (updated)
24/03/2023 Orphan designation: Soluble recombinant human fibroblast growth factor receptor 3 for the: Treatment of achondroplasia, 27/02/2017, Withdrawn (updated)
24/03/2023 Human medicines European public assessment report (EPAR): Zokinvy, Lonafarnib, Progeria; Laminopathies, 18/07/2022, Orphan, Additional monitoring, Exceptional circumstances, 1, Authorised (updated)
24/03/2023 Other: European Union herbal monographs: Overview of recommendations for the uses of herbal medicinal products in the paediatric population (updated)
24/03/2023 Human medicines European public assessment report (EPAR): Taxotere, docetaxel, Head and Neck Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Prostatic Neoplasms; Stomach Neoplasms; Breast Neoplasms, 27/11/1995, 50, Authorised (updated)
24/03/2023 Human medicines European public assessment report (EPAR): Myocet liposomal (previously Myocet), doxorubicin hydrochloride, Breast Neoplasms, 13/07/2000, 24, Authorised (updated)
24/03/2023 Orphan designation: miglustat for the: Treatment of glycogen storage disease type II (Pompe's disease), 11/01/2019, Withdrawn (updated)
24/03/2023 Human medicines European public assessment report (EPAR): Enspryng, satralizumab, Neuromyelitis Optica, 24/06/2021, Orphan, 2, Authorised (updated)
24/03/2023 Human medicines European public assessment report (EPAR): Tamiflu, oseltamivir, Influenza, Human, 20/06/2002, 42, Authorised (updated)
24/03/2023 Human medicines European public assessment report (EPAR): Miglustat Dipharma, miglustat, Gaucher Disease, 18/02/2019, Generic, 5, Authorised (updated)
24/03/2023 Other: HMPC meetings in 2025 and 2026
24/03/2023 Human medicines European public assessment report (EPAR): Brukinsa, zanubrutinib, Waldenstrom Macroglobulinemia, 22/11/2021, Additional monitoring, 5, Authorised (updated)
24/03/2023 Cancer Medicines Forum: June 2022 , Online, from 28/06/2022 to 28/06/2022 (updated)
24/03/2023 Cancer Medicines Forum: December 2022 , Online, from 20/12/2022 to 20/12/2022 (updated)
24/03/2023 Cancer Medicines Forum: kick-off meeting , Online, 08:30 - 12:30 Amsterdam time (CEST), from 31/03/2022 to 31/03/2022 (updated)
23/03/2023 Referral procedures: veterinary medicines (updated)
23/03/2023 EIC / EMA Info Day: Regulatory support for the development of innovative medicines and technologies , Online, 09:00 - 12:30 Amsterdam time (CET), from 31/01/2023 to 31/01/2023 (updated)
23/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Censavudine, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0103/2022
23/03/2023 Orphan designation: Adeno-associated viral vector serotype 2 containing the human SLC6A3 gene for the: Treatment of dopamine transporter deficiency syndrome, 13/01/2023, Positive
23/03/2023 Orphan designation: Autologous CD34+ cells transduced with a lentiviral vector encoding the human NCF1 gene for the: Treatment of chronic granulomatous disease, 13/01/2023, Positive
23/03/2023 Orphan designation: Efzofitimod for the: Treatment of sarcoidosis, 13/01/2023, Positive
23/03/2023 Orphan designation: Opelconazole for the: Treatment of invasive aspergillosis, 13/01/2023, Positive
23/03/2023 Orphan designation: Autologous hematopoietic cells genetically modified with a lentiviral vector containing the human RAG2 gene for the: Treatment of recombination-activating gene 2 deficient severe combined immunodeficiency, 13/01/2023, Positive
23/03/2023 Orphan designation: Nanatinostat, Valganciclovir for the: Treatment of diffuse large B-cell lymphoma, 13/01/2023, Positive
23/03/2023 Orphan designation: Retifanlimab for the: Treatment of Merkel cell carcinoma, 13/01/2023, Positive
23/03/2023 Orphan designation: N1,N14-diethyl-3S,12S-dihydroxyhomospermine tetrahydrochloride for the: Treatment of pancreatic cancer, 13/01/2023, Positive
23/03/2023 Orphan designation: Octreotide acetate for the: Treatment of carcinoid syndrome, 13/01/2023, Positive
23/03/2023 Orphan designation: 3-(1-(2',3'-dimethoxy-[1,1'-biphenyl]-4-yl)-1H-1,2,3-triazol-4-yl)benzoic acid for the: Treatment of Duchenne muscular dystrophy, 13/01/2023, Positive
23/03/2023 Orphan designation: Vorasidenib hemicitrate hemihydrate for the: Treatment of glioma, 13/01/2023, Positive
23/03/2023 Human medicines European public assessment report (EPAR): Truvelog Mix 30, insulin aspart, Diabetes Mellitus, 25/04/2022, Additional monitoring, Biosimilar, 1, Authorised (updated)
23/03/2023 Human medicines European public assessment report (EPAR): Terrosa, teriparatide, Osteoporosis, 04/01/2017, Additional monitoring, Biosimilar, 6, Authorised (updated)
23/03/2023 Human medicines European public assessment report (EPAR): Upstaza, Eladocagene exuparvovec, Amino Acid Metabolism, Inborn Errors, 18/07/2022, Orphan, Additional monitoring, Exceptional circumstances, 3, Authorised (updated)
23/03/2023 Human medicines European public assessment report (EPAR): Dupixent, dupilumab, Dermatitis, Atopic; Prurigo; Esophageal Diseases; Asthma; Sinusitis, 26/09/2017, 25, Authorised (updated)
23/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Idefirix, Imlifidase, PM: decision on the application for modification of an agreed PIP, P/0076/2022 (updated)
23/03/2023 Agenda: Agenda of the CAT meeting 22-23 March 2023
23/03/2023 National registers of authorised medicines (updated)
23/03/2023 Periodic safety update single assessment: Clindamycin phosphate / tretinoin : List of nationally authorised medicinal products - PSUSA/00010080/202207
22/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Piqray, Alpelisib, PM: decision on the application for modification of an agreed PIP, P/0536/2021 (updated)
22/03/2023 Human medicines European public assessment report (EPAR): MabThera, rituximab, Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell, 02/06/1998, 58, Authorised (updated)
22/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Adakveo, Crizanlizumab, PM: decision on the application for modification of an agreed PIP, P/0533/2021 (updated)
22/03/2023 Human medicines European public assessment report (EPAR): Ocrevus, ocrelizumab, Multiple Sclerosis, 08/01/2018, 16, Authorised (updated)
22/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Biktarvy, bictegravir,emtricitabine,tenofovir alafenamide, PM: decision on the application for modification of an agreed PIP, P/0528/2021 (updated)
22/03/2023 Human medicines European public assessment report (EPAR): Kadcyla, trastuzumab emtansine, Breast Neoplasms, 15/11/2013, 15, Authorised (updated)
22/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Juluca, rilpivirine,dolutegravir, PM: decision on the application for modification of an agreed PIP, P/0524/2021 (updated)
22/03/2023 Clinical Trials Information System (CTIS) bitesize talk: Document and personal data in CTIS , Online, 14:30 - 16:00 Amsterdam time (CET), from 23/02/2023 to 23/02/2023 (updated)
22/03/2023 Human medicines European public assessment report (EPAR): Polivy, polatuzumab vedotin, Lymphoma, B-Cell, 16/01/2020, Orphan, Additional monitoring, Conditional approval, 5, Authorised (updated)
22/03/2023 Other: Rules for reimbursement of expenses for delegates attending meetings with effect from 17 March 2023 (updated)
22/03/2023 Human medicines European public assessment report (EPAR): Elebrato Ellipta, fluticasone furoate, umeclidinium bromide, vilanterol trifenatate, Pulmonary Disease, Chronic Obstructive, 15/11/2017, 11, Authorised (updated)
22/03/2023 Human medicines European public assessment report (EPAR): Suliqua, insulin glargine, lixisenatide, Diabetes Mellitus, Type 2, 11/01/2017, 10, Authorised (updated)
22/03/2023 Human medicines European public assessment report (EPAR): Trelegy Ellipta, fluticasone furoate, umeclidinium bromide, vilanterol trifenatate, Pulmonary Disease, Chronic Obstructive, 15/11/2017, 10, Authorised (updated)
22/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): (Z)-N-(3-bromo-4- fluorophenyl)-N-hydroxy-4-(2-(sulfamoylamino)ethylamino)-1,2,5-oxadiazole-3-carboximidamide, PM: decision on the application for modification of an agreed PIP, P/0246/2018 (updated)
22/03/2023 Template or form: QRD Appendix I - Adverse event (PhV) MSs reporting details (updated)
22/03/2023 Human medicines European public assessment report (EPAR): Pradaxa, Dabigatran etexilate mesilate, Arthroplasty, Replacement; Venous Thromboembolism, 17/03/2008, 39, Authorised (updated)
22/03/2023 Human medicines European public assessment report (EPAR): Zynlonta , loncastuximab tesirine, Lymphoma, Large B-Cell, Diffuse; Lymphoma, B-Cell, 20/12/2022, Additional monitoring, Conditional approval, 1, Authorised (updated)
22/03/2023 Human medicines European public assessment report (EPAR): Simponi, Golimumab, Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid, 01/10/2009, 44, Authorised (updated)
22/03/2023 Human medicines European public assessment report (EPAR): Hexacima, hepatitis B surface antigen, Diphtheria toxoid, tetanus toxoid, Bordetella pertussis antigens Pertussis Toxoid Filamentous Haemagglutinin, poliovirus (inactivated) type 1 (Mahoney) type 2 (MEF-1) type 3 (Saukett), Haemophilus influenzae type b polysaccharide (Polyribosylribitol Phosphate) conjugated to Tetanus protein, Hepatitis B; Tetanus; Immunization; Meningitis, Haemophilus; Whooping Cough; Poliomyelitis; Diphtheria, 17/04/2013, 22/02/2013, 28, Authorised (updated)
22/03/2023 Human medicines European public assessment report (EPAR): NovoRapid, insulin aspart, Diabetes Mellitus, 07/09/1999, 32, Authorised (updated)
22/03/2023 Human medicines European public assessment report (EPAR): Blincyto, blinatumomab, Precursor Cell Lymphoblastic Leukemia-Lymphoma, 23/11/2015, Orphan, Additional monitoring, 16, Authorised (updated)
22/03/2023 Human medicines European public assessment report (EPAR): Xolair, omalizumab, Asthma; Urticaria, 25/10/2005, 45, Authorised (updated)
22/03/2023 Human medicines European public assessment report (EPAR): Hexyon, filamentous haemagglutinin, Haemophilus influenzae type B polysaccharide (polyribosylribitol phosphate), hepatitis B surface antigen, pertussis toxoid, poliovirus (inactivated) type 1 (Mahoney strain) produced on Vero cells, poliovirus (inactivated) type 2 (MEF-1 strain) produced on Vero cells, poliovirus (inactivated) type 3 (Saukett strain) produced on Vero cells, tetanus protein, tetanus toxoid adsorbed on aluminium hydroxide, hydrated, Diphtheria toxoid, Hepatitis B; Tetanus; Immunization; Meningitis, Haemophilus; Whooping Cough; Poliomyelitis; Diphtheria, 17/04/2013, 22/02/2013, 29, Authorised (updated)
22/03/2023 Other: Contact details of national competent authorities for requests of translation exemptions falling under Art. 63.3 of Directive 2001/83/EC and cases of shortages (updated)
22/03/2023 Regulatory science strategy (updated)
22/03/2023 News and press releases: Advancing regulatory science in the EU – mid-point report published
22/03/2023 Human medicines European public assessment report (EPAR): Darzalex, Daratumumab, Multiple Myeloma, 20/05/2016, Orphan, Accelerated assessment, 20, Authorised (updated)
22/03/2023 Periodic safety update single assessment: Diltiazem - CMDh Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation - PSUSA/00001084/202205
22/03/2023 Periodic safety update single assessment: Diltiazem - List of nationally authorised medicinal products - PSUSA/00001084/202205
22/03/2023 Human medicines European public assessment report (EPAR): Keppra, levetiracetam, Epilepsy, 29/09/2000, 53, Authorised (updated)
22/03/2023 Human medicines European public assessment report (EPAR): Insulin lispro Sanofi, insulin lispro, Diabetes Mellitus, 19/07/2017, Biosimilar, 8, Authorised (updated)
22/03/2023 Human medicines European public assessment report (EPAR): Herzuma, trastuzumab, Stomach Neoplasms; Breast Neoplasms, 09/02/2018, Biosimilar, 19, Authorised (updated)
22/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Vamorolone, PM: decision on the application for modification of an agreed PIP, P/0515/2021 (updated)
22/03/2023 Human medicines European public assessment report (EPAR): Noxafil, posaconazole, Candidiasis; Mycoses; Coccidioidomycosis; Aspergillosis, 25/10/2005, 36, Authorised (updated)
22/03/2023 Human medicines European public assessment report (EPAR): Ultomiris, ravulizumab, Hemoglobinuria, Paroxysmal, 02/07/2019, Additional monitoring, 10, Authorised (updated)
22/03/2023 Human medicines European public assessment report (EPAR): Imcivree, Setmelanotide, Obesity, 16/07/2021, Orphan, Additional monitoring, 7, Authorised (updated)
22/03/2023 Human medicines European public assessment report (EPAR): Synagis, palivizumab, Respiratory Syncytial Virus Infections, 13/08/1999, 45, Authorised (updated)
22/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Evkeeza, Evinacumab, PM: decision on the application for modification of an agreed PIP, P/0514/2021 (updated)
22/03/2023 Enpr-EMA Coordinating Group meeting , Online, 15:00 - 16:30 Amsterdam time (CET), from 15/02/2023 to 15/02/2023
21/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq, upadacitinib, PM: decision on the application for modification of an agreed PIP, P/0510/2021 (updated)
21/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Molgramostim, PM: decision on the application for modification of an agreed PIP, P/0509/2021 (updated)
21/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Plegridy, peginterferon beta-1a, PM: decision on the application for modification of an agreed PIP, P/0359/2022 (updated)
21/03/2023 Human medicines European public assessment report (EPAR): Evicel, human fibrinogen, human thrombin, Hemostasis, Surgical, 05/10/2008, 17, Authorised (updated)
21/03/2023 Report: 2022 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission
21/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Dovprela (previously Pretomanid FGK), Pretomanid, PM: decision on the application for modification of an agreed PIP, P/0507/2021 (updated)
21/03/2023 Human medicines European public assessment report (EPAR): MicardisPlus, telmisartan, hydrochlorothiazide, Hypertension, 19/04/2002, 33, Authorised (updated)
21/03/2023 Human medicines European public assessment report (EPAR): Lamivudine/Zidovudine Teva, lamivudine, zidovudine, HIV Infections, 28/02/2011, Generic, 16, Withdrawn (updated)
21/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Cotadutide, PM: decision on the application for modification of an agreed PIP, P/0506/2021 (updated)
21/03/2023 Report: 2022 European Medicines Agency annual report on independence
21/03/2023 Human medicines European public assessment report (EPAR): Vihuma, simoctocog alfa, Hemophilia A, 13/02/2017, Additional monitoring, 8, Authorised (updated)
21/03/2023 Human medicines European public assessment report (EPAR): Nuwiq, simoctocog alfa, Hemophilia A, 22/07/2014, 13, Authorised (updated)
21/03/2023 Human medicines European public assessment report (EPAR): Beyfortus, nirsevimab, 31/10/2022, Additional monitoring, 1, Authorised (updated)
21/03/2023 Human medicines European public assessment report (EPAR): Elocta, efmoroctocog alfa, Hemophilia A, 18/11/2015, 12, Authorised (updated)
21/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Lumasiran (ALN-GO1), PM: decision on the application for modification of an agreed PIP, P/0505/2021 (updated)
21/03/2023 Opinion/decision on a Paediatric investigation plan (PIP): Fenfluramine hydrochloride, PM: decision on the application for modification of an agreed PIP, P/0502/2021 (updated)
21/03/2023 Human medicines European public assessment report (EPAR): Inrebic, fedratinib dihydrochloride monohydrate, Myeloproliferative Disorders; Primary Myelofibrosis, 08/02/2021, Orphan, Additional monitoring, 4, Authorised (updated)
21/03/2023 Human medicines European public assessment report (EPAR): Vydura, Rimegepant, Migraine Disorders, 25/04/2022, Additional monitoring, 4, Authorised (updated)
21/03/2023 Human medicines European public assessment report (EPAR): Flucelvax Tetra, A/Wisconsin/588/2019 (H1N1)pdm09-like strain (A/Delaware/55/2019 CVR-45) A/Darwin/6/2021 (H3N2)-like strain (A/Darwin/11/2021, wild type) B/Austria/1359417/2021-like strain (B/Singapore/WUH4618/2021, wild type) B/Phuket/3073/2013-like strain (B/Singapore/INFTT-16-0610/2016, wild type), Influenza, Human, 12/12/2018, Additional monitoring, 12, Authorised (updated)
21/03/2023 Human medicines European public assessment report (EPAR): Revatio, sildenafil, Hypertension, Pulmonary, 28/10/2005, 49, Authorised (updated)
21/03/2023 Human medicines European public assessment report (EPAR): Symtuza, darunavir, cobicistat, emtricitabine, tenofovir alafenamide, HIV Infections, 21/09/2017, 17, Authorised (updated)
21/03/2023 Human medicines European public assessment report (EPAR): Ecalta, anidulafungin, Candidiasis, 20/09/2007, 24, Authorised (updated)
21/03/2023 Human medicines European public assessment report (EPAR): Lucentis, ranibizumab, Wet Macular Degeneration; Macular Edema; Diabetes Complications; Myopia, Degenerative, 22/01/2007, 41, Authorised (updated)
21/03/2023 Orphan designation: Recombinant fusion protein consisting of a modified form of the extracellular domain of human activin receptor IIB linked to the human IgG1 Fc domain (luspatercept) for the: Treatment of beta thalassaemia intermedia and major, 29/07/2014, Positive (updated)
21/03/2023 Human medicines European public assessment report (EPAR): Nevirapine Teva, nevirapine, HIV Infections, 30/11/2009, Generic, 11, Withdrawn (updated)
21/03/2023 Periodic safety update single assessment: Ethinylestradiol / norethisterone : List of nationally authorised medicinal products - PSUSA/00001312/202208
21/03/2023 Periodic safety update single assessment: Alprostadil (indicated in peripheral arterial occlusive diseases) - List of nationally authorised medicinal products - PSUSA/00000111/202207
21/03/2023 EPAR - Public assessment report: Nevirapine Teva : EPAR - Public assessment report (updated)
20/03/2023 Human medicines European public assessment report (EPAR): Aldara, imiquimod, Condylomata Acuminata; Keratosis; Keratosis, Actinic; Carcinoma, Basal Cell, 18/09/1998, 30, Authorised (updated)
20/03/2023 Human medicines European public assessment report (EPAR): Alkindi, hydrocortisone, Adrenal Insufficiency, 09/02/2018, 8, Authorised (updated)
20/03/2023 Human medicines European public assessment report (EPAR): Zomarist, vildagliptin, metformin hydrochloride, Diabetes Mellitus, Type 2, 30/11/2008, 23, Authorised (updated)
20/03/2023 Human medicines European public assessment report (EPAR): Mircera, Methoxy polyethylene glycol-epoetin beta, Anemia; Kidney Failure, Chronic, 20/07/2007, 28, Authorised (updated)
20/03/2023 Human medicines European public assessment report (EPAR): Erivedge, vismodegib, Carcinoma, Basal Cell, 12/07/2013, 26/04/2013, 15, Authorised (updated)
20/03/2023 Clinical Trials Information System (CTIS): Walk-in clinic - October 2023 , Online, 16:00 - 17:00 Amsterdam time (CEST), from 10/10/2023 to 10/10/2023
20/03/2023 Clinical Trials Information System (CTIS): Walk-in clinic - November 2023 , Online, 16:00 - 17:00 Amsterdam time (CET), from 15/11/2023 to 15/11/2023
20/03/2023 Clinical Trials Information System (CTIS): Walk-in clinic - December 2023 , Online, 16:00 - 17:00 Amsterdam time (CET), from 13/12/2023 to 13/12/2023
20/03/2023 Periodic safety update single assessment: Beclometasone formoterol (inhalative application) - List of nationally authorised medicinal products - PSUSA/00010068/202207
20/03/2023 Clinical Trials Information System (CTIS): Walk-in clinic - May 2023 , Online, 16:00 - 17:00 Amsterdam time (CEST), from 17/05/2023 to 17/05/2023
20/03/2023 Clinical Trials Information System (CTIS): Walk-in clinic - June 2023 , Online, 16:00 - 17:00 Amsterdam time (CEST), from 14/06/2023 to 14/06/2023
20/03/2023 Clinical Trials Information System (CTIS): Walk-in clinic - July 2023 , Online, 16:00 - 17:00 Amsterdam time (CEST), from 19/07/2023 to 19/07/2023
20/03/2023 Clinical Trials Information System (CTIS): Walk-in clinic - August 2023 , Online, 16:00 - 17:00 Amsterdam time (CEST), from 23/08/2023 to 23/08/2023
20/03/2023 Clinical Trials Information System (CTIS): Walk-in clinic - September 2023 , Online, 16:00 - 17:00 Amsterdam time (CEST), from 20/09/2023 to 20/09/2023
20/03/2023 Clinical Trials Information System (CTIS): Walk-in clinic - April 2023 , Online, 16:00 - 17:00 Amsterdam time (CEST), from 19/04/2023 to 19/04/2023
20/03/2023 Human medicines European public assessment report (EPAR): Reblozyl, Luspatercept, Anemia; Myelodysplastic Syndromes; beta-Thalassemia, 25/06/2020, Orphan, Additional monitoring, 4, Authorised (updated)
20/03/2023 Periodic safety update single assessment: Triamcinolone topical and nasal formulations - List of nationally authorised medicinal products - PSUSA/00003017/202207
20/03/2023 Minutes: Minutes of the HMPC 23-25 January 2023 meeting
20/03/2023 Agenda: Agenda of the CVMP meeting 21-23 March 2023